SCHEMBL8307608

SCHEMBL8307608

Clc1cccc(-c2cccc(I)c2)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.40
CYP2A6 P11509 1/20 0.40
SCN9A Q15858 1/20 0.40
PTGES2 Q9H7Z7 1/20 0.40
AHR P35869 2/20 0.39
NOTUM Q6P988 1/20 0.37
IDO1 P14902 1/20 0.37
METAP2 P50579 1/20 0.37
CNR1 P21554 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CTSA P10619 1/20 0.36
BCL2L1 Q07817 1/20 0.36
MCL1 Q07820 1/20 0.36
GALR1 P47211 1/20 0.36
TSHR P16473 1/20 0.35
DHODH Q02127 1/20 0.35
PTPN11 Q06124 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27925958 0.86 CYP2A6 (0.58) CYP2A6SCN9AMETAP2CHRNB4CHRNA3
SCHEMBL4445051 0.79 TDO2 (0.44) CNR2CYP2A6SCN9APTGES2AHR
SCHEMBL1032858 0.78 METAP2 (0.44) CYP2A6IDO1METAP2CHRNB4CHRNA3
SCHEMBL29489437 0.76 CYP2A6 (0.68) CNR2CYP2A6NOTUMIDO1BCL2L1
SCHEMBL1250242 0.76 CYP2A6 (0.68) CNR2CYP2A6NOTUMIDO1BCL2L1
SCHEMBL8307816 0.76 MAP4K4 (0.50) CNR2CYP2A6SCN9APTGES2AHR
SCHEMBL8817721 0.76 ACHE (0.42) CNR2CYP2A6SCN9APTGES2AHR
SCHEMBL4452887 0.75 AHR (0.69) CNR2AHRCNR1DHODH
Ammonia Solution, Strong SCHEMBL28700448 0.74 CYP2A6 (0.65) CNR2CYP2A6NOTUMIDO1BCL2L1
SCHEMBL19607480 0.74 BACE1 (0.42) CYP2A6METAP2CHRNB4CHRNA3BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005019200-A2 ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-03-03 WO disclosed